PMID- 30367363
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231004
IS  - 2193-8245 (Print)
IS  - 2193-6528 (Electronic)
VI  - 7
IP  - 2
DP  - 2018 Dec
TI  - Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment 
      Regimens.
PG  - 397-403
LID - 10.1007/s40123-018-0150-x [doi]
AB  - INTRODUCTION: To simplify the medical treatment of glaucoma for patients on 
      multiple drops by introducing brinzolamide/brimonidine tartrate fixed combination 
      (BBFC) ophthalmic suspension 1%/0.2% (SIMBRINZA((R)); Alcon Laboratories, Inc., 
      Fort Worth, TX, USA) to the drop regimen and to establish its efficacy. To 
      demonstrate that fixed combination (FC) therapies are associated with 
      improvements in treatment adherence and persistence with reduced exposure to 
      preservative-related ocular surface problems. METHODS: Retrospective study: 76 
      patients were identified as taking BBFC following a switch in treatment regimen. 
      Intraocular pressure (IOP) prior to and 2-17.5 months (average 5.4 months) after 
      the introduction of BBFC was measured. The change in the average number of 
      bottles used per eye was recorded. The rate of adverse effects (AEs) of BBFC was 
      recorded. A two-tailed paired sample t test was used to compare IOP prior to and 
      after the introduction of BBFC for each eye. RESULTS: Mean change in IOP after 
      BBFC introduction BBFC: - 2.76 mmHg (p < 0.0001). BBFC intolerance: 13%. On 
      average there was a 0.24 reduction in the number of bottles of IOP-lowering 
      medication used per eye (p < 0.0064). CONCLUSION: A switch to BBFC in the drop 
      regimen is associated with a significant drop in IOP with reduced drop burden. 
      Instead of a third IOP-lowering medication and bottle, a practitioner should 
      consider using BBFC + prostaglandin analogue/FC drop for effective IOP control, 
      reduced drop burden, reduced preservative load and increased likelihood of 
      adherence. This study promotes the concept that any treatment should principally 
      be assessed from the patients' perspective and quality of life.
FAU - Moosavi, Reza
AU  - Moosavi R
AD  - Eye Ear and Mouth Unit, Maidstone and Tunbridge Wells NHS Trust, Maidstone 
      Hospital, Maidstone, UK. rezamoosavi@nhs.net.
FAU - Ansari, Ejaz
AU  - Ansari E
AD  - Eye Ear and Mouth Unit, Maidstone and Tunbridge Wells NHS Trust, Maidstone 
      Hospital, Maidstone, UK.
LA  - eng
PT  - Journal Article
DEP - 20181026
PL  - England
TA  - Ophthalmol Ther
JT  - Ophthalmology and therapy
JID - 101634502
PMC - PMC6258589
OTO - NOTNLM
OT  - Brinzolamide-brimonidine fixed combination
OT  - Ophthalmology
OT  - Simbrinza
EDAT- 2018/10/28 06:00
MHDA- 2018/10/28 06:01
PMCR- 2018/10/26
CRDT- 2018/10/28 06:00
PHST- 2018/07/16 00:00 [received]
PHST- 2018/10/28 06:00 [pubmed]
PHST- 2018/10/28 06:01 [medline]
PHST- 2018/10/28 06:00 [entrez]
PHST- 2018/10/26 00:00 [pmc-release]
AID - 10.1007/s40123-018-0150-x [pii]
AID - 150 [pii]
AID - 10.1007/s40123-018-0150-x [doi]
PST - ppublish
SO  - Ophthalmol Ther. 2018 Dec;7(2):397-403. doi: 10.1007/s40123-018-0150-x. Epub 2018 
      Oct 26.